期刊文献+

Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs.identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia

下载PDF
导出
摘要 Objective:We aimed to compare the quality-adjusted time without symptoms or toxicity(Q-TWiST)in acute myeloid leukemia(AML)patients who received haploidentical-related donor(HID)and identical sibling donor(ISD)hematopoietic stem cell transplantation(HSCT).Methods:Five clinical health states were defined:toxicity(TOX),acute graft-versus-host disease(GVHD),chronic GVHD(cGVHD),time without symptoms and toxicity(TWiST)and relapse(REL).The equation used in this study was as follows:Q-TWiST=UTOX×TOX+UTWiST×TWiST+UREL×REL+UaGVHD×aGVHD+UcGVHD×cGVHD.Results:A total of 239 AML patients were enrolled.We established a mathematical model,i.e.,Q-TWiST HID HSCT>Q-TWiST ISD HSCT,to explore the range of utility coefficients satisfying the inequality.Based on the raw data,the utility coefficient is equivalent to the following inequality:10.57067UTOX-46.27733UREL+105.9374+3.388078UaGVHD-210.8198UcGVHD>0.The model showed that when UTOX,UREL,and UaGVHD were within the range of 0-1,as well as when UcGVHD was within the range of 0-0.569,the inequality Q-TWiST HID HSCT>Q-TWiST ISD HSCT was valid.According to the results of the ChiCTR1800016972 study,the median coefficients of TOX,acute GVHD(aGVHD),and cGVHD were 0.56(0.41-0.76),0.56(0.47-0.72),and 0.54(0.37-0.79),respectively.We selected a series of specific examples of the coefficients,i.e.,UTOX=0.5,UREL=0.05,UaGVHD-0.5,and UcGVHD-0.5.The Q-TWiST values of ISD and HID HSCT were 896 and 900 d,respectively(P=0.470).Conclusions:We first observed that Q-TWiST was comparable between AML patients receiving HID HSCT and those receiving ISD HSCT.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2024年第5期530-544,共15页 中国癌症研究(英文版)
基金 supported by the Key Program of the National Natural Science Foundation of China(No.81930004) the National Natural Science Foundation of China(No.82170208) Tongzhou District Distinguished Young Scholars(No.JCQN2023009) Plan Project of Tongzhou Municipal Science and Technology(No.KJ2024CX045) Beijing Natural Science Foundation(No.Z230016)。
  • 相关文献

参考文献6

二级参考文献46

  • 1Schaefer L, Iozzo RV. Biological functions of the small leucine- rich proteoglycans: from genetics to signal transduction. J Biol Chem, 2008,283:21305-21309.
  • 2Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J, 2010,277:3864-3875.
  • 3Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res, 2010,339: 237- 246.
  • 4Iozzo RV, Chakrani F, Perrotti D, et al. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A, 1999,96:3092-3097.
  • 5Bi X, Tong C, Dockendorff A, et al. Genetic deficiency o1 decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis, 2008,29:1435-1440.
  • 6Csordas G, Santra M, Reed CC, et al. Sustained down- regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem, 2000.275:32879 - 32887.
  • 7Santra M, Eichstetter I, Iozzo RV. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem, 2000,275:35153-35161.
  • 8Gialeli C, Kletsas B, Mavroudis D, et al. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr Med Chem, 2009,16:3797-3804.
  • 9Zhu JX, Goldoni S, Bix G, et al. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem, 2005,280: 32468-32479.
  • 10Reed CC, Waterhouse A, Kirby S, et al. Decorin prevents metastatic spreading of breast cancer. Oncogene, 2005,24: 1104-1110.

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部